Background: High levels of serum Interleukin-6 correlate with disease severity in COVID-19 pneumonia We hypothesized that tocilizumab (a recombinant humanized
Tocilizumab to Prevent Ventilatory Support for Severe Worsening COVID-19 Pneumonia: A Propensity Score Analysis